{"id":"NCT03605862","sponsor":"Romark Laboratories L.C.","briefTitle":"Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection","officialTitle":"A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-09-11","primaryCompletion":"2019-02-04","completion":"2019-02-04","firstPosted":"2018-07-30","resultsPosted":"2022-04-14","lastUpdate":"2022-04-14"},"enrollment":1756,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Enterovirus","Rhinovirus"],"interventions":[{"type":"DRUG","name":"Nitazoxanide","otherNames":["NTZ (nitazoxanide)","NT-300"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Nitazoxanide","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Trial to evaluate efficacy and safety of nitazoxanide in the treatment of colds due to Enterovirus/Rhinovirus infection","primaryOutcome":{"measure":"Time From First Dose to Symptom Response Over 21 Days of Follow up Based Upon the FLU-PRO Instrument (Novel Endpoint)","timeFrame":"Up to 21 days","effectByArm":[{"arm":"Nitazoxanide","deltaMin":122.5,"sd":null},{"arm":"Placebo","deltaMin":137.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4009"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":45,"countries":["United States","Puerto Rico"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":872},"commonTop":["Chromaturia","Diarrhoea","Nausea"]}}